Prokaryotics recieves $2.5 Million SBIR Grant to endorse Novel Antibiotic Program

Prokaryotics receives $2.5 million from the National Institute of Allergy and Infectious Diseases as a SBIR. The two-year agreement will fund research by Prokaryotics on the restoration of beta-lactam efficacy against methicillin-resistant Staphylococci..

$299,999 will fund studies to improve potency and pharmacokinetic parameters of the adjuvant. Contingent on the success of the first phase, second phase funds of $2.2 million will be used to drive towards selection of a single pre-clinical candidate which could be paired with intravenous as well as orally-administered beta-lactam antibiotics to treat MRSA infections in both hospital and out-patient settings.

Terry Roemer, Ph.D., founder and chief scientific officer of Prokaryotics claimed “We greatly appreciate NIAID’s leadership in providing research funding for such a critical area, where new antibiotics are critically needed to treat patients with infections caused by multi-drug resistant pathogens, including MRSA”.

The relentless advance of the antibiotic drug resistant bacteria has raised concerns whether within the next 2-3 decades we could be facing a ‘pre-antibiotic era’ where existing antibiotics will become largely ineffective in treating serious and life-threatening infections.  Indeed, the World Health Organization has projected that the impact on human health and economic costs associated with antibiotic drug resistance will rival that of global warming.

 

 

 

Comments (0)
Add Comment